Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiglucerase maximum-dose treatment in Chinese patients with Gaucher disease type III
2024-000041-27Phase 4
- Sponsor
- Sanofi
- Start
- Feb 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imiglucerase in Gaucher disease type 3, sponsored by Sanofi. Primary endpoint: Change in hemoglobin.
02
Drugs
imiglucerase
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on 2024-000041-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000041-27.